GC Biopharma sells US vaccine unit to Eli Lilly in $1.5b deal

GC Biopharma said Wednesday that it would transfer its US affiliate Curevo Vaccine to Eli Lilly and Company in a deal worth up to $1.5 billion.

Under the agreement, Lilly will acquire all shares of Curevo and secure rights to amezosvatein, the affiliate’s herpes zoster vaccine candidate currently under development.

The deal includes an upfront payment upon closing as well as milestone payments tied to future development and commercialization achievements, GC Biopharma said.

The company said the ...